Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with University of Wisconsin Researchers for Clinical Pharmacology Studies Evaluating TRP-8803

  • Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison
  • The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation
  • The partnership is the latest in a series of collaborations as the company prepares for Phase 2b trials
  • Tryp intends to use data from its Phase 2a clinical studies, expected to launch this year, coupled with preclinical data and clinical pharmacology data for TRP-8803, to support the use of the novel drug formulation in Phase 2b trials

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a company leading the next wave of psychedelics beyond mental health and unleashing the full potential of psilocybin for conditions with unmet needs, recently announced a collaboration with researchers at the University of Wisconsin-Madison, as part of preparations toward the planned Phase 2b studies (https://ibn.fm/Rt60z).

Under the partnership, Dr. Paul Hutson, PharmD, a Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy, and Dr. Christopher Nicholas, PhD, an Assistant Professor at the University of Wisconsin-Madison School of Medicine and Public Health, will support…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

 

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.